HPB/NET disease group, Christie supporters
The HPB/NET disease group at The Christie recently took part in The Christie skydive and Glow in the Park. This helped to raise vital funds and awareness for research into Hepatopancreaticobiliary (HPB) cancers and Neuroendocrine tumours (NETs).
One of the team members said: "The prognosis for patients with these cancers is poor, resulting in short survival and diminished quality of life. This has not improved significantly over the last 5 years. More research is desperately required to improve quality of life and survival for patients diagnosed with these cancers."
Another team member said: “All of our lives have been touched by these diagnoses, either personally or professionally, and challenging ourselves to step outside of our comfort zones to contribute, even a little, towards funding research for a potential breakthrough is a communal goal”.
The HPB/NET disease group at The Christie has an active clinical research programme with close links to basic scientific research laboratories in the Cancer Research UK (CRUK) Manchester Institute and the Wolfson Molecular Imaging Centre. There is an established record of clinical research in HPB/NET, and the aim is to develop this further through collaboration with other academic centres nationally and internationally.
The group has an international reputation in the treatment of advanced biliary tract cancer and neuroendocrine tumours (accredited as a Centre of Excellence by the European NET Society in 2011 and re-accredited in 2019). There are around 500 new patient HPB/NET referrals received per year by the disease group, and approximately 25 percent of all patients are entered in to clinical trials.
Overall, more than £3,100 has been raised from the skydive and over £1,000 from Glow in the Park. That gives them an amazing total of just over £4,100 so far!